Evidence map›Paper›PMID 30030659›Full record

ReviewWorld journal of urology2019

Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.

Christian Daniel Fankhauser, Cédric Poyet, Stephanie G C Kroeze, Benedikt Kranzbühler, Helena I Garcia Schüler, Matthias Guckenberger, Philipp A Kaufmann, Thomas Hermanns, Irene A Burger

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Annals of nuclear medicine · 2021
    Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Christian Daniel FankhauserDepartment of Urology, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland. christian.fankhauser@usz.ch.
Cédric PoyetDepartment of Urology, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland.
Stephanie G C KroezeDepartment of Radiation Oncology, University of Zurich, Zurich, Switzerland.
Benedikt KranzbühlerDepartment of Urology, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland.
Helena I Garcia SchülerDepartment of Radiation Oncology, University of Zurich, Zurich, Switzerland.
Matthias GuckenbergerDepartment of Radiation Oncology, University of Zurich, Zurich, Switzerland.
Philipp A KaufmannDepartment of Nuclear Medicine, University of Zurich, Zurich, Switzerland.
Thomas HermannsDepartment of Urology, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland.
Irene A BurgerDepartment of Nuclear Medicine, University of Zurich, Zurich, Switzerland.
University of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo review the current literature and discuss potential future roles of the novel positron emission tomography (PET) tracers targeting the prostate-specific membrane antigen (PSMA) in patients with castration-resistant prostate cancer (CRPC).

methodsA literature search on February 19th 2018 was conducted using the Medline database and www.clinicaltrials.gov . Additionally, illustrative cases of CRPC patients from our own institution who were restaged and treated based on PSMA-PET scan results are provided.

results11 Studies met the inclusion criteria. PSMA-PET detected more metastatic lesions compared to conventional bone scan. Several patients were up-staged from non-metastatic CRPC (nmCRPC) to metastatic CRPC (mCRPC). Currently, no clear consensus exists regarding treatment response assessment in PSMA-PET scans for mCRPC patients undergoing treatment. Also, the role of PSMA-PET as a gatekeeper for systemic therapy or radioligands is currently undefined. PSMA-guided metastasis-directed radiotherapy may not only alleviate local symptoms but has the potential to defer systemic treatment in patients with oligoprogressive CRPC.

conclusionCompared to bone scan, PSMA-PET is more sensitive and specific to detect metastases but the therapeutic consequences of PSMA-PET results in the setting of CRPC remain unclear. Until future studies define the role of PSMA-PET in patients with CRPC, the current standard for imaging remains bone scan and computerized tomography.

Indexed as

Membrane GlycoproteinsOrganometallic CompoundsRadiopharmaceuticalsBone NeoplasmsGallium IsotopesGallium RadioisotopesHumansMaleNeoplasm StagingPositron-Emission TomographyProstatic Neoplasms, Castration-ResistantRadionuclide ImagingTomography, X-Ray Computedgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesMembrane GlycoproteinsOrganometallic CompoundsRadiopharmaceuticals(68)Ga-PSMACRPCPositron emission tomography computed tomographyProstatic neoplasmsReview

Identifiers

PMID30030659
OpenAlexW2883507327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.